Department of Epidemiology University of Alabama at Birmingham AL.
Division of Cardiovascular Disease Department of Medicine University of Alabama at Birmingham AL.
J Am Heart Assoc. 2022 Jun 7;11(11):e025397. doi: 10.1161/JAHA.121.025397. Epub 2022 May 27.
Background It is unclear whether lipoprotein(a) is associated with coronary heart disease (CHD) and ischemic stroke events in White and Black adults with atherosclerotic cardiovascular disease (ASCVD). Methods and Results We conducted a case-cohort analysis, including Black and White REGARDS (Reasons for Geographic and Racial Differences in Stroke) study participants ≥45 years of age with prevalent ASCVD (ie, CHD or stroke) at baseline between 2003 and 2007. Baseline lipoprotein(a) molar concentration was measured in participants with ASCVD who experienced a CHD event by December 2017 (n=1166) or an ischemic stroke by September 2019 (n=492) and in a random subcohort of participants with prevalent ASCVD (n=1948). The hazard ratio (HR) for CHD events per 1 SD (1.5 units) higher log-transformed lipoprotein(a) was 1.26 (95% CI, 1.02-1.56) among Black participants and 1.16 (95% CI, 1.02-1.31) among White participants ( value comparing HRs, 0.485). The HR for CHD events per 1 SD higher log-lipoprotein(a) within subgroups with hs-CRP (high-sensitivity C-reactive protein) ≥2 and <2 mg/L was 1.31 (95% CI, 0.99-1.73) and 1.23 (95% CI, 0.85-1.80), respectively ( value comparing HRs, 0.836), among Black participants, and 1.07 (95% CI, 0.91-1.27) and 1.36 (95% CI, 1.10-1.70), respectively ( value comparing HRs, 0.088), among White participants. There was no evidence that the association between lipoprotein(a) and CHD events differed by statin use. There was no evidence of an association between lipoprotein(a) and ischemic stroke events among Black or White participants. Conclusions Higher lipoprotein(a) levels were associated with an increased risk for CHD events in Black and White adults with ASCVD.
背景:脂蛋白(a) 是否与白人和黑人患有动脉粥样硬化性心血管疾病 (ASCVD) 的成年人的冠心病 (CHD) 和缺血性卒中事件相关尚不清楚。
方法和结果:我们进行了病例-队列分析,纳入了 2003 年至 2007 年期间基线时患有 ASCVD(即 CHD 或卒中)的≥45 岁的黑人及白人 REGARDS(地理和种族差异导致的卒中原因)研究参与者。在 2017 年 12 月之前发生 CHD 事件的 ASCVD 患者(n=1166)或 2019 年 9 月之前发生缺血性卒中的患者(n=492)和随机选择的具有 ASCVD 的患者亚组(n=1948)中,测量了基线脂蛋白(a)摩尔浓度。黑人参与者中,每增加 1 个标准差 (1.5 个单位) 的脂蛋白(a),CHD 事件的风险比 (HR) 为 1.26 (95%CI,1.02-1.56),白人参与者中为 1.16 (95%CI,1.02-1.31)(比较 HR 值的 值,0.485)。在 hs-CRP(高敏 C 反应蛋白)≥2 和 <2 mg/L 的亚组内,脂蛋白(a)每增加 1 个标准差的 HR 分别为 1.31 (95%CI,0.99-1.73) 和 1.23 (95%CI,0.85-1.80)(比较 HR 值的 值,0.836),黑人参与者;分别为 1.07 (95%CI,0.91-1.27) 和 1.36 (95%CI,1.10-1.70)(比较 HR 值的 值,0.088),白人参与者。没有证据表明脂蛋白(a)与 CHD 事件之间的关联因他汀类药物的使用而有所不同。没有证据表明脂蛋白(a)与黑人或白人参与者的缺血性卒中事件之间存在关联。
结论:在患有 ASCVD 的黑人和白人成年人中,较高的脂蛋白(a)水平与 CHD 事件风险增加相关。
J Am Heart Assoc. 2020-3-17
Am J Prev Cardiol. 2025-2-14
Lipids Health Dis. 2024-9-27
JACC Adv. 2023-8-21
J Am Heart Assoc. 2024-6-18
J Am Heart Assoc. 2023-9-19
JACC Cardiovasc Interv. 2021-9-27
Arterioscler Thromb Vasc Biol. 2021-1
J Am Coll Cardiol. 2019-11-19